ES2182327T3 - DERIVATIVES OF (IMIDAZOL-5-IL) METHYL-2-QUINLINONE AS INHIBITORS OF THE PROLIFERATION OF SMOOTH MUSCLE CELLS. - Google Patents

DERIVATIVES OF (IMIDAZOL-5-IL) METHYL-2-QUINLINONE AS INHIBITORS OF THE PROLIFERATION OF SMOOTH MUSCLE CELLS.

Info

Publication number
ES2182327T3
ES2182327T3 ES98928332T ES98928332T ES2182327T3 ES 2182327 T3 ES2182327 T3 ES 2182327T3 ES 98928332 T ES98928332 T ES 98928332T ES 98928332 T ES98928332 T ES 98928332T ES 2182327 T3 ES2182327 T3 ES 2182327T3
Authority
ES
Spain
Prior art keywords
sub
alkyl
sup
amino
alkyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98928332T
Other languages
Spanish (es)
Inventor
David William End
Michael J Zelesko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2182327T3 publication Critical patent/ES2182327T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al empleo de compuestos de fórmula (I) en los que la línea de puntos representa un enlace opcional; X es oxigeno azufre; R{sup, 1} es H, alquilo C{sub, 1-12}, Ar{sup,1}, Ar{sup,2} alquilo -C{sub, 1-6}, quinolinil alquilo C{sub, 1-6}, piridinil C{sub, 1-6} alquilo, hidroxi alquilo C{sub, 1-6}, C{sub, 1-6} alcoxilo, alquilo C{sub, 1-6}, mono- o di(alquil C{sub, 1-6})amino alquilo C{sub, 1-6}, amino alquilo C{sub, 1-6}, o un radical de la fórmula -Alq {suo,1}-C(=O)-R{sup,9}, -Alq {sup,1}-S(O)-R{sup, 9}, o -Arq{sup,1}-S(O){sub,2}-R{sup, 9}; R{sup, 2}, R{sup, 3} y R{sup, 17}, cada uno independientemente son H, hidroxi, halo, ciano, alquilo C{sub, 1-6}, C{sub, 1-6} alcoxilo, hidorxi- alquiloxi C{sub, 1-6}, alquiloxi C{sub, 1-6}, amino alquiloxi C{sub, 1-6}, mono-o di(alquil C{sub, 1-6})amino alquiloxi C{sub, 1-6}, Ar{sup,1}, Ar{sup,2} alquilo C{sub, 1-6}, Ar{sup,2} oxi, Ar{sup,2}, alquiloxi C{sub, 1-6}, hidroxicarbonilo, alquiloxicarbonilo C{sub, 1-6}, trihalometilo, trihalometoxi, alquenilo C{sub, 2-6}, R{sup, 4} y R{sup, 5} cada uno independinetemente son H, Ar{sup,1}, alquilo C{sub, 1-6}, hidoroxi- alquilo C{sub, 1-6}, alquiloxi C{sub, 1-6}, alquilo C{sub, 1-6}, alquiloxi C{sub, 1-6}, alquiltio C{sub, 1-6}, amino, hidorcarbonilo, alquiloxicarbonilo C{sub, 1-6}, alquil C{sub, 1-6} S(O) alquilo C{sub, 1-6} o alquil C{sub, 1-6} S(O){sub,2} alquilo C{sub, 1-6}; R{sup,6} y R{sup,7} cada uno independientemente son H, halo, ciano, C{sub, 1-6} alquilo, 4,4-dimetil -oxazolilo, C{sub, 1-6}alquiloxilo o Ar{sup,2}oxy; R{sup,8} es H, C{sub, 1-6} alquilo, ciano, hidroxicarbonilo, C{sub, 1-6} alquiloxicarbonilo, C{sub, 1-6} alquilcarbonilo, C{sub, 1-6} alquilo, cianoC{sub, 1-6} alquilo, C{sub, 1-6} alquiloxicarbonil C{sub, 1-6} alquilo, alcoxi C{sub, 1-6} alquilo, hidroxi C{sub, 1-6} alquilo, amino C1-6 alquilo, mono-o di(C{sub, 1-6}alquil)amino C{sub, 1-6}alquilo, imidazolilo, halo, alquilo C{sub,1-6}, alcoxi C{sub,1-6} alquilo C{sub,1-6}, aminocarbonil alquilo C{sub,1-6} o u radical de fórmula -O-R{sup, 10}, -S-R{sup, 10}, -N-R{sup, 11}, O{sup, 12}; R{sup, 17} es H, halo, ciano, alquilo C{sub, 1-6}, alquiloxicarbonilo C{sub, 1-6}, Ar{sup,1}; R{sup, 18} es H, alquilo C{sub, 1-6}, alcoxilo o halo C{sub, 1-6}; R{sup, 19} es H o alquilo C{sub, 1-6} para la fabricación de un medicamento que inhibe la proliferación de células de músculo liso.The invention relates to the use of compounds of formula (I) in which the dotted line represents an optional bond; X is sulfur oxygen; R {sup, 1} is H, C {sub, 1-12} alkyl, Ar {sup, 1}, Ar {sup, 2} -C {sub, 1-6} alkyl, quinolinyl C {sub, 1 alkyl -6}, pyridinyl C {sub, 1-6} alkyl, hydroxy C {sub, 1-6} alkyl, C {sub, 1-6} alkoxy, C {sub, 1-6} alkyl, mono- or di (C {sub, 1-6} alkyl) amino C {sub, 1-6} alkyl, amino C {sub, 1-6} alkyl, or a radical of the formula -Alq {suo, 1} -C (= O) -R {sup, 9}, -Alq {sup, 1} -S (O) -R {sup, 9}, or -Arq {sup, 1} -S (O) {sub, 2} -R {sup, 9}; R {sup, 2}, R {sup, 3} and R {sup, 17}, each independently are H, hydroxy, halo, cyano, C {sub, 1-6} alkyl, C {sub, 1-6 } alkoxy, C {sub, 1-6} hydroxy-alkyloxy, C {sub, 1-6} alkyloxy, C {sub, 1-6} amino, mono- or di (C {sub, 1-6 alkyl) ) amino C {sub, 1-6}, Ar {sup, 1}, Ar {sup, 2} C {sub, 1-6} alkyl, Ar {sup, 2} oxy, Ar {sup, 2}, C {sub, 1-6} alkyloxy, hydroxycarbonyl, C {sub, 1-6} alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C {sub, 2-6} alkenyl, R {sup, 4} and R {sup, 5} each one independently is H, Ar {sup, 1}, C {sub, 1-6} alkyl, C {sub, 1-6} hydroxy-alkyl, C {sub, 1-6} alkyloxy, C {sub, 1 alkyl -6}, C {sub, 1-6} alkyloxy, C {sub, 1-6} alkylthio, amino, hydrocarbonyl, C {sub, 1-6} alkyloxycarbonyl, C {sub, 1-6} S alkyl (O ) C {sub, 1-6} alkyl or C {sub, 1-6} S (O) {sub, 2} C {sub, 1-6} alkyl; R {sup, 6} and R {sup, 7} each independently are H, halo, cyano, C {sub, 1-6} alkyl, 4,4-dimethyl -oxazolyl, C {sub, 1-6} alkyloxy or Ar {sup, 2} oxy; R {sup, 8} is H, C {sub, 1-6} alkyl, cyano, hydroxycarbonyl, C {sub, 1-6} alkyloxycarbonyl, C {sub, 1-6} alkylcarbonyl, C {sub, 1-6 } alkyl, cyanoC {sub, 1-6} alkyl, C {sub, 1-6} alkyloxycarbonyl C {sub, 1-6} alkyl, C {sub alkoxy, 1-6} alkyl, C {sub, 1- hydroxy 6} alkyl, amino C1-6 alkyl, mono- or di (C {sub, 1-6} alkyl) amino C {sub, 1-6} alkyl, imidazolyl, halo, C {sub, 1-6} alkyl, C {sub, 1-6} alkoxy C {sub, 1-6} alkyl, aminocarbonyl C {sub, 1-6} alkyl or radical of formula -OR {sup, 10}, -SR {sup, 10}, - NR {sup, 11}, O {sup, 12}; R {sup, 17} is H, halo, cyano, C {sub, 1-6} alkyl, C {sub, 1-6} alkyloxycarbonyl, Ar {sup, 1}; R {sup, 18} is H, C {sub, 1-6} alkyl, alkoxy or C {sub, 1-6} halo; R {sup, 19} is H or C {sub, 1-6} alkyl for the manufacture of a medicament that inhibits the proliferation of smooth muscle cells.

ES98928332T 1997-06-02 1998-05-25 DERIVATIVES OF (IMIDAZOL-5-IL) METHYL-2-QUINLINONE AS INHIBITORS OF THE PROLIFERATION OF SMOOTH MUSCLE CELLS. Expired - Lifetime ES2182327T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4737697P 1997-06-02 1997-06-02

Publications (1)

Publication Number Publication Date
ES2182327T3 true ES2182327T3 (en) 2003-03-01

Family

ID=21948611

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98928332T Expired - Lifetime ES2182327T3 (en) 1997-06-02 1998-05-25 DERIVATIVES OF (IMIDAZOL-5-IL) METHYL-2-QUINLINONE AS INHIBITORS OF THE PROLIFERATION OF SMOOTH MUSCLE CELLS.

Country Status (21)

Country Link
US (4) US6365600B1 (en)
EP (1) EP0988038B1 (en)
JP (1) JP4209472B2 (en)
KR (1) KR100517832B1 (en)
CN (2) CN100525766C (en)
AT (1) ATE222104T1 (en)
AU (1) AU740603B2 (en)
BR (1) BR9810423A (en)
CA (1) CA2290992C (en)
DE (1) DE69807222T2 (en)
DK (1) DK0988038T3 (en)
ES (1) ES2182327T3 (en)
ID (1) ID24675A (en)
IL (1) IL133212A (en)
NO (1) NO318834B1 (en)
NZ (1) NZ501401A (en)
PT (1) PT988038E (en)
RU (1) RU2209066C2 (en)
TR (1) TR199902923T2 (en)
WO (1) WO1998055124A1 (en)
ZA (1) ZA984700B (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100525766C (en) 1997-06-02 2009-08-12 詹森药业有限公司 (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
US20020099438A1 (en) * 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
HRP20000904A2 (en) * 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US7967855B2 (en) 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
DE69923849T2 (en) * 1998-08-27 2006-01-12 Pfizer Products Inc., Groton QUINOLIN-2-ON DERIVATIVES USE AS ANTICROPHOSIS
DK1140935T3 (en) * 1998-12-23 2003-09-01 Janssen Pharmaceutica Nv 1,2-celled quinoline derivatives
SK11002001A3 (en) 1999-02-11 2002-05-09 Pfizer Products Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
PT1106612E (en) * 1999-11-30 2004-06-30 Pfizer Prod Inc USEFUL QUINOLINE DERIVATIVES TO INHIBIT FARNESIL-PROTEIN-TRANSFERASE
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Farnesyl transferase inhibiting 1-2 annelated quinoline enantiomer
CZ304344B6 (en) 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Quinolinone derivatives and their use as well as pharmaceutical compositions in which the derivatives are comprised
FR2813791B1 (en) * 2000-09-14 2004-03-12 Lafon Labor USE OF 2- AND 4-QUINOLONES TO INHIBIT INTIMAL NEO-PROLIFERATION
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
WO2002024686A2 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
JP4974437B2 (en) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 6-[(Substituted phenyl) methyl] -quinoline and quinazoline derivatives that inhibit farnesyltransferase
DE60118225T2 (en) 2000-09-25 2007-05-03 Janssen Pharmaceutica N.V. CHINOLIN AND CHINAZOLINE DERIVATIVES AND THEIR USE AS FARNESYL TRANSFERASE INHIBITORS
AU2002214056A1 (en) 2000-11-21 2002-06-03 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
JP4351445B2 (en) 2000-12-27 2009-10-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 4-Substituted-quinoline and quinazoline derivatives that inhibit farnesyltransferase
EP1408971A4 (en) 2001-06-21 2006-01-25 Ariad Pharma Inc Novel quinolines and uses thereof
EP1458720B1 (en) 2001-12-19 2009-03-18 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1490065B1 (en) 2002-03-22 2007-06-13 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
DE60307616T2 (en) 2002-04-15 2007-10-04 Janssen Pharmaceutica N.V. FARNESYL TRANSFERASE-INHIBITING TRICYCLIC QUINAZOLE DERIVATIVES SUBSTITUTES WITH CARBIDE-BONDED IMIDAZOLS OR TRIAZOLS
US8016881B2 (en) 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US6638301B1 (en) * 2002-10-02 2003-10-28 Scimed Life Systems, Inc. Medical device with radiopacity
AU2003290699B2 (en) 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
US20050154451A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
EA011359B1 (en) * 2004-01-23 2009-02-27 Янссен Фармацевтика Н.В. Substituted quinolines and their use as mycobacterial inhibitors
US7211108B2 (en) * 2004-01-23 2007-05-01 Icon Medical Corp. Vascular grafts with amphiphilic block copolymer coatings
US7875624B2 (en) 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
CN1930127B (en) * 2004-03-15 2012-11-21 阿诺麦德股份有限公司 Process for the synthesis of cxcr4 antagonist
CA2559282A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2559285A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US7063720B2 (en) * 2004-09-14 2006-06-20 The Wallace Enterprises, Inc. Covered stent with controlled therapeutic agent diffusion
US20060083770A1 (en) * 2004-10-15 2006-04-20 Specialty Coating Systems, Inc. Medical devices and methods of preparation and use
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060200048A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Removable sheath for device protection
JP5335244B2 (en) 2005-03-03 2013-11-06 アイコン メディカル コーポレーション Medical member using improved metal alloy
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
WO2006110197A2 (en) 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
MX2007014782A (en) 2005-05-23 2008-02-19 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts.
CA2617213C (en) 2005-07-29 2014-01-28 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
EP1968591A4 (en) 2005-12-23 2010-02-17 Link Medicine Corp Treatment of synucleinopathies
US20070148390A1 (en) * 2005-12-27 2007-06-28 Specialty Coating Systems, Inc. Fluorinated coatings
CN101663262B (en) * 2006-12-01 2014-03-26 百时美施贵宝公司 N-(3-benzyl)-2,2-(diphenyl)-propan-1amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
AU2008256928A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
KR101629356B1 (en) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 Methods of preparing quinazolinone derivatives
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012508768A (en) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
NZ755378A (en) 2009-03-18 2022-07-29 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
KR20190091564A (en) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 Novel anti-inflammatory agents
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
RU2640115C2 (en) 2011-11-01 2017-12-26 Ресверлоджикс Корп. Pharmaceutical compositions of substituted quinazolinones
CN104093709B (en) * 2012-02-13 2017-09-22 霍夫曼-拉罗奇有限公司 It is used as the imidazole derivative of aldosterone synthase inhibitors
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
ES2619610T3 (en) * 2012-10-16 2017-06-26 Janssen Pharmaceutica Nv ROR-gamma-t modulators of heteroaryl-linked quinolinyl
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
ES2742843T3 (en) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv ROR quinolinyl modulators (gamma) t
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
BR112016008215A2 (en) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv roryt alkyl-linked quinolinyl modulators
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2015199816A1 (en) 2014-06-24 2015-12-30 Icon Medical Corp. Improved metal alloys for medical devices
US20210322651A1 (en) * 2014-12-18 2021-10-21 Senex Biotechnology, Inc. Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors
JO3789B1 (en) 2015-03-13 2021-01-31 Resverlogix Corp Compositions and therapeutic methods for the treatment of complement -associated diseases
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
HUE044698T2 (en) 2015-08-17 2019-11-28 Kura Oncology Inc Methods of treating cancer patients with farnesyl transferase inhibitors
CN109069426B (en) 2015-12-14 2021-10-29 X4 制药有限公司 Methods of treating cancer
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
PL3393468T3 (en) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. METHODS OF TREATING IMMUNODEFICIENCE
WO2017151548A1 (en) 2016-03-04 2017-09-08 Mirus Llc Stent device for spinal fusion
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109640988A (en) 2016-06-21 2019-04-16 X4 制药有限公司 CXCR4 inhibitors and their uses
ES2870920T3 (en) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc CXCR4 inhibitors and their uses
JP2019534290A (en) 2016-11-03 2019-11-28 クラ オンコロジー， インコーポレイテッド Farnesyltransferase inhibitors for use in methods of treating cancer
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN110204487B (en) * 2019-06-21 2021-09-28 江南大学 Synthesis method of quinoline derivative
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
CN113072490B (en) * 2021-03-26 2022-08-16 中国海洋大学 High-efficiency synthesis method of tipifarnib quinolinone intermediate
CN119371281A (en) * 2024-12-27 2025-01-28 山东石油化工学院 A method for alkyl chloride substitution with CH2Cl2 participating in C-H bond activation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE456347B (en) 1982-02-09 1988-09-26 Ird Biomaterial Ab SURFACE MODIFIED SOLID SUBSTRATE AND PROCEDURES FOR PRODUCING THEREOF
US5213898A (en) 1989-10-12 1993-05-25 Norsk Hydro A.S. Process for the preparation of surface modified solid substrates
US5049403A (en) 1989-10-12 1991-09-17 Horsk Hydro A.S. Process for the preparation of surface modified solid substrates
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5356433A (en) 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
JPH07112930A (en) * 1993-10-14 1995-05-02 Kyowa Hakko Kogyo Co Ltd Vascular smooth muscle cell growth inhibitor
DE69623455T2 (en) 1995-04-19 2003-01-16 Schneider (Usa) Inc., Plymouth COATED DILATATOR FOR DISPOSING A MEDICINAL PRODUCT
US5607475A (en) 1995-08-22 1997-03-04 Medtronic, Inc. Biocompatible medical article and method
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (en) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (IMIDAZOL-5-YL) METHYL-2-CHINOLINO DERIVATIVES AS A FARNESYL PROTEIN TRANSFERASE INHIBITOR
CN100525766C (en) 1997-06-02 2009-08-12 詹森药业有限公司 (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation

Also Published As

Publication number Publication date
US20020091138A1 (en) 2002-07-11
TR199902923T2 (en) 2000-11-21
HK1025046A1 (en) 2000-11-03
KR20010012782A (en) 2001-02-26
CN1762355A (en) 2006-04-26
US6734194B2 (en) 2004-05-11
NO995883L (en) 2000-02-02
KR100517832B1 (en) 2005-09-30
ID24675A (en) 2000-07-27
US6365600B1 (en) 2002-04-02
IL133212A (en) 2005-12-18
NO318834B1 (en) 2005-05-09
CN1231215C (en) 2005-12-14
WO1998055124A1 (en) 1998-12-10
US6743805B2 (en) 2004-06-01
US20030229118A1 (en) 2003-12-11
BR9810423A (en) 2000-10-03
ZA984700B (en) 1999-12-01
DE69807222T2 (en) 2003-04-17
PT988038E (en) 2002-12-31
RU2209066C2 (en) 2003-07-27
NZ501401A (en) 2002-03-28
US7253183B2 (en) 2007-08-07
DK0988038T3 (en) 2002-12-02
IL133212A0 (en) 2001-03-19
HK1088820A1 (en) 2006-11-17
JP2002503235A (en) 2002-01-29
DE69807222D1 (en) 2002-09-19
AU740603B2 (en) 2001-11-08
CA2290992C (en) 2008-02-12
ATE222104T1 (en) 2002-08-15
CN1265585A (en) 2000-09-06
JP4209472B2 (en) 2009-01-14
CN100525766C (en) 2009-08-12
NO995883D0 (en) 1999-12-01
EP0988038A1 (en) 2000-03-29
US20040198771A1 (en) 2004-10-07
CA2290992A1 (en) 1998-12-10
EP0988038B1 (en) 2002-08-14
AU8020798A (en) 1998-12-21

Similar Documents

Publication Publication Date Title
ES2182327T3 (en) DERIVATIVES OF (IMIDAZOL-5-IL) METHYL-2-QUINLINONE AS INHIBITORS OF THE PROLIFERATION OF SMOOTH MUSCLE CELLS.
ES2171736T3 (en) DERIVATIVES OF 2-QUINOLONA INHIBITORS OF FARNESIL-TRANSFERASA.
ES2189235T3 (en) 6-REPLACED PHENYLPHENANTRIDINS.
UY27522A1 (en) PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
BG102458A (en) (imidazol-5-yl)methyl-2-quinoline derivatives inhibiting pharnesyl protein transferase
UA70958C2 (en) A method for the treatment of disease related to disorder of estrogen metabolisme (variants)
DE69810328D1 (en) COMPILATION OF MIXED CYANOACRYLATE ESTERS
SE0301886D0 (en) New use V
SE0301882D0 (en) New use I
UY28674A1 (en) 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 INHIBITORS AMINO
YU3902A (en) Imidazoimidiazoles and triazoles as anti-inflamatory agents
ES2193508T3 (en) FTALIZINONES.
CO4920241A1 (en) HETERO-CYCLIC METALOPROTEASE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR ITS USE
ES2152414T3 (en) DIHYDROBENZOFURANS.
ATE276241T1 (en) ANTIOXIDANT
ES2189207T3 (en) INHIBITORS OF REVERSED HYDROXAMATES OF MARY METALOPROTEINASES.
TR200301723T4 (en) 1,3 Dihydro-2H-indol-2 one derivatives and their use as binding agents for V1B or V1B receptors of arginine-vasopressin
SV2002000244A (en) METHODS AND COMPOUNDS TO INHIBIT MRP1 REF.X-13353
PT979079E (en) USE OF TETRA-HYDROPYRIDINE DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES THAT CAUSE A DEMELINIZATION
AR117951A1 (en) TRIAZOLQUINOXALINE DERIVATIVES ADDITIONALLY SUBSTITUTED
ATE17727T1 (en) ALKYLENE-BRIDGE GUANIDINOTHIAZOL DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS.
MX9700854A (en) DERIVATIVES OF AZABICICLOHEPTANO N-SUBSTITUTED USEFUL AS NEUROLEPTICOS.
DK0986393T3 (en) Use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
ES2189184T3 (en) FUNGICIDE BLENDS.
CO5210926A1 (en) FUNGICIDE BLENDS